Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 7:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–42 of 18 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Metabolic Health, Elevated Liver Enzymes, Digestive Symptoms
Interventions
Plant-Based Liquid Supplement
Dietary Supplement
Lead sponsor
Biocol Labs
Industry
Eligibility
40 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Las Vegas, Nevada
Conditions
Non-verbal Learning Disorder, Autism Spectrum Disorder, Autism
Interventions
Open-label Treatment with Omega-3 Fatty Acids + Inositol, Open-label Treatment with N-acetylcysteine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
5 Years to 17 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Polycystic Ovary Syndrome
Interventions
pioglitazone, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Richmond, Virginia
Completed Phase 4 Interventional Results available

Inositol and Omega-3 Fatty Acids in Pediatric Mania

NCT01396486
Conditions
Pediatric Bipolar Spectrum Disorders
Interventions
Omega-3, Inositol
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
5 Years to 12 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Not applicable Interventional Accepts healthy volunteers

Nutrition21 Study 1

NCT04828278
Conditions
Nutritional Supplementation
Interventions
Arginine, Placebo
Dietary Supplement
Lead sponsor
Texas A&M University
Other
Eligibility
18 Years to 40 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
College Station, Texas
Conditions
Pregnancy Related
Interventions
Myo-inositol, Myo-inositol placebo
Dietary Supplement
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Polycystic Ovary Syndrome
Interventions
DCI, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Richmond, Virginia
Completed Not applicable Interventional Accepts healthy volunteers

Cystatin SN Binds to Phytic Acid and Predicts Non-heme Iron Bioavailability

NCT03030703
Conditions
Iron-deficiency, Iron Deficiency Anemia
Interventions
phytic acid
Dietary Supplement
Lead sponsor
Kansas State University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Manhattan, Kansas
Completed Not applicable Interventional Accepts healthy volunteers

Evaluating the Effect of a Supplement on Symptoms of Hormonal Imbalance.

NCT06535698
Conditions
Women's Health
Interventions
Perelel Health Hormonal Balance Support
Dietary Supplement
Lead sponsor
Perelel Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Santa Monica, California
Not listed Not applicable Interventional Accepts healthy volunteers

Glycemic Impact of Myo-inositol in Pregnancy

NCT02149992
Conditions
Gestational Diabetes Mellitus as Antepartum Condition
Interventions
myo-inositol, Continuous glucose monitoring surveillance, Glucose monitoring
Dietary Supplement · Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
13 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Non-small Cell Lung Cancer, Squamous Lung Dysplasia
Interventions
placebo, inositol
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
45 Years to 79 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
3
States / cities
Scottsdale, Arizona • Rochester, Minnesota • Albuquerque, New Mexico
Conditions
Alzheimer's Disease
Interventions
ELND005 (scyllo-inositol)
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
Not listed
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
30
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 27 more
Conditions
Alzheimer's Disease
Interventions
ELND005, Placebo
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
50 Years to 95 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
57
States / cities
Birmingham, Alabama • Phoenix, Arizona • Encino, California + 50 more
Conditions
Bipolar Disorder
Interventions
Lithium Carbonate
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2004
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Alzheimer Disease
Interventions
Placebo Control, ELND005
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
50
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 44 more
Terminated Phase 3 Interventional Results available

Inositol to Reduce Retinopathy of Prematurity

NCT01954082
Conditions
Retinopathy of Prematurity (ROP)
Interventions
myo-Inositol 5% Injection, Placebo
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
12 Hours to 72 Hours
Enrollment
638 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 15 more
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Retinopathy of Prematurity, Bronchopulmonary Dysplasia (BPD)
Interventions
Inositol lower volume, Inositol higher volume, Placebo lower volume, Placebo higher volume
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
3 Days to 6 Days
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
11
States / cities
New Haven, Connecticut • Indianapolis, Indiana • Detroit, Michigan + 7 more
Conditions
IUGR, Pregnancy
Interventions
Mannose, Myoinositol, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2016
U.S. locations
1
States / cities
Aurora, Colorado